Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGM - Nasdaq Real Time Price USD

AtriCure, Inc. (ATRC)

Compare

31.83

-2.54

(-7.39%)

At close: March 28 at 4:00:01 PM EDT

31.83

0.00

(0.00%)

After hours: March 28 at 5:31:58 PM EDT

AtriCure to Host Analyst & Investor Day on March 26, 2025

MASON, Ohio, March 12, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET.

Business Wire 18 days ago

ATRC
-7.39%
AtriCure Full Year 2024 Earnings: EPS Misses Expectations

AtriCure ( NASDAQ:ATRC ) Full Year 2024 Results Key Financial Results Revenue: US$465.3m (up 17% from FY 2023). Net...

Simply Wall St. last month

ATRC
-7.39%
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

ATRC
-7.39%
Q4 2024 AtriCure Inc Earnings Call

Q4 2024 AtriCure Inc Earnings Call

Thomson Reuters StreetEvents last month

ATRC
-7.39%
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks last month

ANAB

ATRC
-7.39%
AtriCure Inc (ATRC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

AtriCure Inc (ATRC) reports a 17% revenue increase in 2024, driven by new product launches and robust international sales, despite challenges in gross margin and R&D expenses.

GuruFocus.com last month

ATRC
-7.39%
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks last month

ATRC
-7.39%
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates

AtriCure (ATRC) delivered earnings and revenue surprises of 46.67% and 0.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ATRC
-7.39%
AtriCure: Q4 Earnings Snapshot

The Mason, Ohio-based company said it had a loss of 33 cents per share. Losses, adjusted for non-recurring costs, came to 8 cents per share. The medical device maker posted revenue of $124.3 million in the period.

Associated Press Finance last month

ATRC
-7.39%
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

MASON, Ohio, February 12, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results.

Business Wire last month

ATRC
-7.39%
Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS

Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Zacks last month

ATRC
-7.39%
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

BIO-B

ATRC
-7.39%
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

ATRC
-7.39%
Why AtriCure, Inc. (ATRC) Is Skyrocketing Now

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where AtriCure, Inc. (NASDAQ:ATRC) stands against the other stocks that are skyrocketing now. The market has started to favor smaller companies in 2025, and stocks between $1 billion and $5 […]

Insider Monkey 2 months ago

ATRC
-7.39%
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results

MASON, Ohio, January 22, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025.

Business Wire 2 months ago

ATRC
-7.39%
Brainsway (BWAY) Moves 8.0% Higher: Will This Strength Last?

Brainsway (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 2 months ago

BWAY

ATRC
-7.39%
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

MASON, Ohio, January 13, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025.

Business Wire 2 months ago

ATRC
-7.39%
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

MASON, Ohio, December 23, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference.

Business Wire 3 months ago

ATRC
-7.39%
AtriCure, Inc. (NASDAQ:ATRC) Shares Could Be 26% Below Their Intrinsic Value Estimate

Key Insights AtriCure's estimated fair value is US$49.02 based on 2 Stage Free Cash Flow to Equity AtriCure is...

Simply Wall St. 3 months ago

ATRC
-7.39%
AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

MASON, Ohio, November 20, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 36th Annual Healthcare Conference.

Business Wire 4 months ago

ATRC
-7.39%

Performance Overview

Return	ATRC	S&P 500 (^GSPC)
YTD	+4.16%	-5.11%
1-Year	+4.64%	+6.22%
3-Year	-49.11%	+21.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AtriCure, Inc. (ATRC)

AtriCure to Host Analyst & Investor Day on March 26, 2025

AtriCure Full Year 2024 Earnings: EPS Misses Expectations

AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know

Q4 2024 AtriCure Inc Earnings Call

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

AtriCure Inc (ATRC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings

AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates

AtriCure: Q4 Earnings Snapshot

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know

Why AtriCure, Inc. (ATRC) Is Skyrocketing Now

AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results

Brainsway (BWAY) Moves 8.0% Higher: Will This Strength Last?

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

AtriCure, Inc. (NASDAQ:ATRC) Shares Could Be 26% Below Their Intrinsic Value Estimate

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

Performance Overview